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Antibody response to hepatitis b immunization in Egyptian children with 
sickle cell disease  
 
INTRODUCTION 
Most patients with SCD will be transfused with red 
blood cells during their lives for the treatment or 
prevention of SCD related complications. Despite 
improvement in the safety of blood products, SCD 
patients are at greater risk than the general 
population for hepatitis B infection and chronic 
liver disease, making hepatitis B immunization 
especially important for this population1. In 
addition, SCD is associated with impaired humoral 
responsiveness caused by splenic hypofunction2 
Hepatitis B virus (HBV) infection acquired during 
infancy and early childhood is a major cause of 
liver disease and liver cancer worldwide3. The 
World Health Organization has recommended that 
all infants receive hepatitis B vaccination4,5. In 
Egypt, vaccination against HBV is compulsory 
since 1992 by three intramuscular injections into 
the deltoid muscle of 0.5 ml of vaccine at age of 2, 
4 and 6 months. Substantial reductions in the 
prevalence of chronic infection and the incidence of 
acute hepatitis B have been demonstrated among 
children in populations where routine infant 
hepatitis B vaccination has been implemented6-9. 
However, the duration of protection after infants are 
vaccinated is unknown10,11. 
The argument about the need of revaccination 
against HBV at 5 years interval encouraged us to 
conduct this work to explore the validity of the 
protective titer and the need for booster dose in 
such immunodeficient patients. The aim of this 
study was to evaluate and follow up the antibody 
response to hepatitis B vaccination in these 
pediatric SCD patients after 1 to 15 years of starting 
obligatory vaccination schedule. 
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Background: Despite improvement in the safety of blood products, sickle 
cell disease (SCD) and thalassemic patients are at greater risk than the 
general population for hepatitis B infection and chronic liver disease, 
making hepatitis B immunization especially important for this population. 
This study was conducted to evaluate and follow up the antibody response to 
hepatitis B vaccination, in patients with SCD, after 1-15 years of 
vaccination. Methods: participants were 30 SCD and 30 thalassemic 
patients attending the Hematology Department, Children’s Hospital, Cairo 
University as well as 30 ages and sex matched normal controls. They were 
subjected to clinical evaluation, complete blood count, and measurement of 
liver transaminases, serum bilirubin, and serum ferritin levels as well as 
estimation of anti-HBs titer by enzymatic immunoassay. Results: Anti-HBs 
titers in SCD patients ranged between 5.6 and 381 IU/L (54.83 ± 15.30), 
while the levels of thalassemic patients ranged between 16 and 343 IU/L 
(93.4 ± 30) and those of the control group ranged from 10 to 523 IU/L (83.4
± 28.1) which revealed statistically significant decrease in SCD patients 
compared to thalassemic and healthy controls (p =0.0317).  Out of the 30
SCD patients, 40% showed anti-HBs titer below 10 IU/L (non-protective 
titer), while none of the thalassemic patients or the control group revealed 
the same. Achievement of a protective titer had no correlation with sex, 
consanguinity, or any of the clinical or laboratory data tested. Conclusion: 
Immune dysfunction in thalassemia is not playing a major role in response 
to hepatitis B vaccination. However, SCD children should have their anti-
HBs titer measured after routine hepatitis B immunization to ensure that 
they achieved protective titer, then after 1 year of vaccination and repeated 
every 5 years and those who do not seroconvert should receive additional 
doses.  Booster HBV vaccination of unprotected SCD patients seems 
mandatory. 
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METHODS 
Patients were consecutively enrolled among sickle 
cell disease and thalassemic patients previously 
diagnosed by complete blood count and HB 
electrophoresis and attending the Hematology 
Department, Children’s Hospital, Cairo University 
after fulfilling the inclusion criteria. All candidates 
had received hepatitis B vaccine according to the 
compulsory schedule of vaccination in Egypt, by 
three intramuscular injections of 0.5 ml of the 
recombinant vaccine at 2, 4 and 6 months. 
Inclusion criteria: All SCD patients were in a 
quiescent state.   
Exclusion criteria: SCD patients suffering from 
vaso-occlusive crisis, acute infection, dehydration 
and those on immunosuppressive medications for 
treatment of any associated pathology at the time of 
study recruitment . 
Participants were enrolled after obtaining an 
informed consent from each child's parent/guardian. 
The study included 30 pediatric sickle cell 
disease patients.  Their age ranged from 2 to 15.6 
years (7.8±0.7), they were 14 males (46.7%) and 16 
females (53.3%). They were compared to 30 
thalassemic patients (mean age 9.2±1.5) and 30 age 
and sex matched subjects as a control group. 
Children's medical charts including birth records 
were reviewed to ascertain receival of the primary 
immunization schedule and to assure that no 
additional hepatitis B vaccine doses had been 
received.                                                    
All patients were subjected to: History taking, 
clinical examination, complete blood counting with 
manual differential, and estimation of liver 
transaminases, serum bilirubin, and serum ferritin 
levels as well as measurement of anti-HBs titer. 
Specimen collection: The blood specimen collected 
by venipuncture, allowed clotting. Serum was then 
separated by centrifugation at 1500 rpm and kept 
frozen (-20 degree or below) until used.  Grossly 
haemolyzed samples as well as those containing 
particulate matter or exhibiting obvious microbial 
contamination were excluded. 
Quantitative determination of serum ferritin 
level was carried out for patients and controls by 
Abbot Axsym system (Abbot diagnostic division. 
Longford Co., Ireland). Quantitative Estimation of 
anti-HBs antibody titer done by enzyme 
immunoassay technique (EIA) (AUSAB; Abbott 
Laboratories, Abbott Park, IL, USA)  
Principle of enzyme immunoassay: The technique 
is used for quantitative determination of anti-HBs 
titer in serum. Anti-HBs from sample  is added to a 
well coated with HBsAg, incubated for 2 hours at 
37 degree then washed, after washing enzyme tracer 
is added, incubated for 1 hour at 37 degree then 
washed. The presence of anti-HBs allows the 
enzyme tracer to bind to the solid phase. The 
enzyme activity is therefore proportional to the 
concentration of anti-HBs present in sample or 
calibrators. Enzyme activity is measured by adding 
a colorless chromogen/substrate solution. The 
enzyme action on it produces a color which is 
measured with a photometer. 
Interpretations of results: It is generally accepted 
that an anti-HBs concentration above 10 IU/L is 
indicative of a protective titer or positive response to 
vaccination. Antibody concentration below 10 IU/L 
is indicative of absence of acquired immunity12. 
 
Statistical analysis: Statistical analysis was 
conducted using Microsoft Excel version 7 
(Microsoft Corporation, NY, USA) and SPSS 
(Statistical Package for the Social Science). Data 
were statistically described in terms of mean ± 
standard error (± SE) and frequencies (percentages) 
when appropriate. Comparison of quantitative 
variables between the study groups were performed 
using the Mann Whitney U test and (ANOVA) tests. 
For comparing categorical data, Chi-square (χ2) test 
and Yates correction equation were used. A 
probability value (p value) less than 0.05 considered 




Descriptive and frequencies of clinical data of 
sickle cell and thalassemic patients are illustrated in 
Table (1, 2) respectively. 
Concerning iron chelation, deferoxamine was 
used only in 5 sickle cell (16.7%) and 6 thalassemic 
patients (20%) while deferiprone was used in 2 
sickle cell (6.6%) and 18 thalassemic (60%) 
patients. 
Anti-hepatitis B surface (Anti-HBs) titers in 
sickle cell patients ranged from 5.6 to 381 IU/L 
(54.83 ± 15.3), while in thalassemic patients it 
ranged between 16 and 343 IU/L  (93.4 ± 30) and in 
the control group it ranged between 10 and 
523(83.4 ± 28.1). Comparison between the 3 groups 
shows statistically significant decrease (p<0.05) in 
SCD patients as compared to the other 2 groups 
(Table 4). 
Out of our 30 sickle cell patients, 12 (40%) 
were below the protective level against hepatitis B 
infection i.e. below 10 IU/L. while none of the 
thalassemic patients or the control group revealed 
the same . 
In our study, the frequency of protected SCD 
patients tended to increase with age (Table 5). 
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Table 1. Descriptive clinical data of sickle cell and thalassemic patients 
Sickle cell patients Thalassemic patients Variables Mean SE SD Mean SE SD 
Age (yr) 
Age at presentation (yr) 
Age at first blood transfusion(yr 
No. of blood transfusion / year 
No. of crisis / year 
No. of attacks of fever / year 





































Table 2. Frequencies of clinical data of sickle cell disease and thalassemic patients. 
Variables Percentage of sickle cell patients Percentage 










Consanguinity 21 (70%) 12(40%) 
Family history 15 (50%) 15(50%) 
Spleen 











Hepatomegaly 22(73.3%) 24 (80%) 
Vasocclusive crisis 
- Acute abdomen 
- Back pain 
- Dactilitis 







Causes of Hospitalization 









Table 3. Descriptive laboratory data of sickle cell and thalassemic patients. 
Sickle cell patients Thalassemic patients Variables Range Mean SE SD Range Mean SE SD 
RBCs x million /ul 2-4.5 2.8 0.1 0.6 2.5-3.6 3.1 0.1 0.4 
Hb /dl 5.1-11 7.6 0.3 1.4 6-8 6.9 0.2 0.6 
HCT (%) 16.4-30 22.8 0.6 3.2 18-27 22.5 0.9 2.7 
MCV (fl) 60.9-113 83.4 1.9 10.6 53-68 61 1.9 5.9 
WBCs/thousand/ul 3.5-33.3 12.3 1.2 6.8 3.9-11.2 7.4 0.7 2.2 
Neutrophils % 35.5-75 53.1 1.8 9.7 32-60 45.5 3 9.5 
Lymphocytes % 18-60 39.7 1.7 9.3 37-64 50.7 2.9 9.2 
Platelet thousand/ul 130-698 320.3 29.2 160.1 250-1250 688.8 97.6 308.8
Serum ferritin/ug/dl  134-3060 1072.2 312.7 1188.2 530-3480 1639 280.3 886.4
Total bilirubin/mg/dl 0.6-3.7 1.8 0.2 1.1 0.8-4.8 2.6 0.4 1.4 
Direct bilirubin (mg/dl) 0.04-2.07 0.8 0.3 1.4 0.2-0.8 0.5 0.07 0.2 
HCT: hematocrit; MCV: mean corpuscular volume; RBCs: red blood cells; WBCs: white blood cells; SD: 
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Table 4. Comparison between anti-HBs titer of SCD patients, 




No. = 30 
Mean ± SE 
Thalassemic patients
 No. =30  
Mean ± SE 
Control 








Table 5. Relation between age of SCD patients and anti-HBs titer. 
 Below 5 years
No.=11 
5 to 10 years
No.=11 
Above 10 years 
No.=8 
Protected 
Anti-HBS ≥10 IU/L 5 (45.4%) 7 (63.6%) 6 (75%) 
Unprotected 
Anti-HBS <10 IU/L 6 (55.6%) 4 (36.4%) 2 (25%) 
 
There were a tendency towards a positive 
correlation between anti-HBs titer (IU/L) in sickle 
cell patients and neutrophilic count, and  negative 
ones  between anti-HBs titer (IU/L) in these 
patients and age of first blood transfusion,   number 
of attacks of fever per year, number of hospital 
admission per year and serum ferritin level (ug/dl). 
However, these correlations did not reach 




Our results indicate that after starting obligatory 
vaccination, the antibody response to hepatitis B 
vaccine is significantly lower in patients with SCD, 
compared to thalassemic patients and the normal 
population. This is demonstrated in two ways. 
Statistically significant low anti-HBs titer was 
observed in SCD patients compared to thalassemic 
patients and control groups p=0.0317 (Table 4). In 
addition, out of our 30 sickle cell patients, 12 (40%) 
patients lie below the protective level against 
hepatitis B infection i.e. below 10 IU/L. while none 
of the thalassemic patients or the control group 
demonstrated such finding. 
In SCD, the presence of additional factors 
contributing to immune deficiency may offer an 
explanation. The immunological response in SCD 
patients may be different; this disease is associated 
with frequent and often severe infections because of 
immune function impairment and functional 
asplenia13. This immunologic dysfunction 
associated with SCD is documented in literature. 
The most common two diseases associated with the 
development of hyposplenism are sickle cell 
anemia and celiac disease. Hyposplenism is 
relatively easy to recognize by typical changes 
observed on the peripheral blood smear; including 
Howell-Jolly bodies, monocytosis, lymphocytosis, 
and increased platelet counts. Diagnosis can be 
confirmed by 99Tc-labelled radio colloid scan of 
the spleen; wherever available14. 
A prospective study conducted in Qatif (Eastern 
Province of Saudi Arabia) to study the splenic 
function among (SCA) patients, using (99m)Tc 
stannous colloid liver-spleen scan during the steady 
state proved that: 70% of patients had evidence of 
splenic hypofunction, and most of them (83%) had 
severe hyposplenism15. In addition, splenic function 
studied in 72 Omani SCD patients according to 
their colloid uptake revealed that, 20 (28%) had 
severe hyposplenism; and 26 (36%) patients had 
functional asplenia16. A Kuwaiti study demonstrates 
that the phagocytic  function of the spleen, which is 
tested by colloid uptake, is the first to be lost while 
the filtration function, tested by denatured RBC 
uptake, persists for much longer17. 
This sequence of loss of spleen function may 
explain the tendency of hyposplenic subject to 
develop fatal invasive disease. Overwhelming 
pneumococcal sepsis accounts for most cases of 
mortality in hyposplenic subjects14. Inhibitors of 
normal T lymphocytes appear to be present in a 
significant percentage of SCD sera, which inhibits 
normal lymphocyte response to phytohemagglutinin 
(PHA) in vitro even during the steady state of 
disease18. 
Similar to our results is a study conducted in 
the Children's Hospital Medical Center of Akron, 
Ohio on 150 children with SCD. It observed that 
89% of SCD children are seroprotected in 
comparison to 97% in the general population 
(P=0.002). The authors concluded that children 
with SCD do not respond to hepatitis B 
immunization as efficiently as the general 
population. They were unable to clearly 
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demonstrate a correlation between age, sex, or SCD 
subtype and humoral responsiveness19. 
On the contrary, a study on the immunization 
status of 30 SCD patients, 5 years post hepatitis B 
vaccination, was conducted by the University of 
West Indies in St Augustine, Trinidad and Tobago. 
It revealed that there was no significant difference 
between SCD patients and normal controls in the 
levels of antibody or in the numbers that required 
booster vaccination20. 
Our study revealed that thalassemic patients 
and normal children could maintain a protective 
level of anti-hepatitis B surface antibody. These 
results are supported by relevant studies conducted 
in the Hematology Clinic, New Children’s Hospital, 
Cairo University on thalassemic patients. In 1993, 
the HBsAg positivity detected was 16.48%21 while 
recently in 2009 a study that included 50 
thalassemic patients revealed that hepatitis B virus 
infection occurred in one patient only (2%)22. These 
results reflect the protective impact of the 
obligatory hepatitis B vaccination, which started in 
Egypt since 1992. 
An Egyptian study assessing the long-term 
immunity to hepatitis B among 720 healthy 10 
years children, who were vaccinated in infancy, 
concluded that up to 10 years, booster doses are 
unnecessary possibly due to protective anamnestic 
response to antigenic challenge23. An Italian study 
noted that, a strong immunological memory persists 
more than 10 years after immunization of infants 
and adolescents with a primary course of 
vaccination. Booster doses of vaccine did not seem 
necessary to ensure long-term protection24. A study 
conducted on 1355 Saudi students showed the 
excellent efficacy of the HBV vaccination program 
in Saudi Arabia 18 years after its launch25. 
On the contrary, another recent Egyptian study 
assessed the long-term immunity to hepatitis B 
among 242 Egyptian children aged 6-12 years who 
had received a full vaccination course in infancy. It 
showed that only 39.4% had protective hepatitis B 
surface antibodies titer26. Also, a study conducted in 
Taiwan that involved 5875 new university entrants 
concluded that a booster dose of HB vaccine, given 
18 years following HB vaccination, perhaps even 
earlier, should be considered27. 
However, certain percentage of vaccinees will 
be non responsive or hypo responsive to HBV 
vaccination; this is specially true for patients with 
chronic liver disease28, renal disease or 
haemodialysis  (HD), since these patients lose 
hepatitis B immunity both after natural infection or 
vaccination29. In children with cancer, the immune 
response maintains a protective level of anti-HBs in 
about 60% of cases after vaccination, despite 
immunosuppression30. In this study, it is surprising 
that the SCD patients who were vaccinated since 5 
years showed a higher incidence of low titer 
(unprotected)   compared to those vaccinated since 
10 years or more (Table 5).  This might be 
explained by the fact that repeated exposures to 
HBV through multiple blood transfusion stimulated  
immune memory by natural boosting31 which is 
more likely common with increasing age, however 
the factors that stimulate the immune mechanism in 
some children and not in others are still the field of 
extended studies. The findings are also limited by 
the sample size. 
In Conclusion, Sickle cell disease patients need 
follow up of their immune response to HBV 
vaccination; since in our study up to 40% did not 
achieve protective titer against HB. On the other 
hand, the immune dysfunction in thalassemia does 
not seem to play a major role in response to 
hepatitis B vaccination. 
We recommend that, anti-HBs titer should be 
measured after routine hepatitis B immunization 
then after 1 year of vaccination and every 5 years in 
SCD patients. Those who do not seroconvert should 
receive additional doses of the hepatitis B vaccine. 
Revaccination of the unprotected patients is 
mandatory and must be followed carefully till the 
protective immune level is achieved. 
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